Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
D016907:Adverse Drug Reaction Reporting Systems; D002243:Carbolines / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017091:Colitis, Ischemic / Q000139:chemically induced* / Q000453:epidemiology; D003109:Colonic Diseases, Functional / Q000175:diagnosis / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced* / Q000453:epidemiology; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D009656:North America; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D002243:Carbolines; C090840:alosetron